Chris Garabedian

Chris Garabedian is a seasoned executive with extensive experience in the life sciences and healthcare sectors. Currently serving as Chairman and CEO of Xontogeny since June 2016, Garabedian also holds the position of Portfolio Manager for the PXV Fund at Perceptive Advisors. In addition to these roles, Garabedian is an active board member for several companies, including AsclepiX Therapeutics, CereVasc, and Zucara Therapeutics. Previous leadership positions include Chairman of the Board for Landos Biopharma and Forge Biologics, as well as a tenure as Chief Executive Officer at Sarepta Therapeutics from 2011 to 2015. Garabedian's advisory expertise was further honed during a five-year term as a Senior Advisor to the Healthcare Practice at The Boston Consulting Group. Chris Garabedian earned a B.S. in Marketing from the University of Maryland between 1985 and 1989.